These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23220403)

  • 41. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
    Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells.
    Suzuki Y; Yasui H; Brzoska T; Mogami H; Urano T
    Blood; 2011 Sep; 118(11):3182-5. PubMed ID: 21791417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What drives "fibrinolysis"?
    Medcalf RL
    Hamostaseologie; 2015; 35(4):303-10. PubMed ID: 25564072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
    Schneider M; Nesheim M
    J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
    Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
    Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
    Hauptmann J; Glusa E
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
    Bu C; Gao L; Xie W; Zhang J; He Y; Cai G; McCrae KR
    Arthritis Rheum; 2009 Feb; 60(2):559-68. PubMed ID: 19180513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
    Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
    J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpesviruses enhance fibrin clot lysis.
    Gershom ES; Vanden Hoek AL; Meixner SC; Sutherland MR; Pryzdial EL
    Thromb Haemost; 2012 Apr; 107(4):760-8. PubMed ID: 22318336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Physical determinants of fibrinolysis in single fibrin fibers.
    Bucay I; O'Brien ET; Wulfe SD; Superfine R; Wolberg AS; Falvo MR; Hudson NE
    PLoS One; 2015; 10(2):e0116350. PubMed ID: 25714359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
    Akassoglou K; Kombrinck KW; Degen JL; Strickland S
    J Cell Biol; 2000 May; 149(5):1157-66. PubMed ID: 10831618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Redistribution of TPA Fluxes in the Presence of PAI-1 Regulates Spatial Thrombolysis.
    Shibeko AM; Chopard B; Hoekstra AG; Panteleev MA
    Biophys J; 2020 Aug; 119(3):638-651. PubMed ID: 32653051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visualizing the degradation of fibrin fibers.
    Risman RA; Tutwiler V
    Biophys Rev (Melville); 2024 Sep; 5(3):032101. PubMed ID: 38962393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma fibronectin enhances fibrinolytic system in vitro.
    Gilboa N; Kaplan JE
    Thromb Haemost; 1985 Oct; 54(3):639-44. PubMed ID: 2935966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.